Clinical trial
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced…
NCT00391586 · New Mexico Cancer Research Alliance, Other · Terminated
Key facts
| NCT number | NCT00391586 |
|---|---|
| Title | Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung |
| Official title | INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung |
| Lead sponsor | New Mexico Cancer Research Alliance, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Erlotinib, Platinum-based chemotherapy |
| Enrollment | 45 |
| Start date | Jul 1, 2006 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2012 |
| First posted | Oct 24, 2006 |
| Last update posted | Aug 17, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: